Genmab — Juni 2020
-
TV kombinationstudiet i cervical cancer har estimated primary completion date i april 2021https://clinicaltrials.gov/ct2/show/NCT03786081?cond=tisotumab+vedotin&draw=2&rank=8
-
Iovance LN-145 viste ORR på 44% ved ASCO 2019 på 27 pre-treated, recurrent cervical cancer patienter. Bliver nok en hård konkurrent til TV, men er jo nok et års tid bagefter tidsmæssigt https://www.evaluate.com/vantage/articles/news/snippets/asco-2019-iovance-enjoys-pre-asco-bounce
-
Bryan Garnier hæver fair value til 2150 fra 2000. Fortsat Neutral
-
BG: A 24% ORR puts it at the forefront of the cervical space
-
BG: TV seems to have an edge over Keytruda in 2L+ setting
-
BG: This success paves the way for 1L use
-
BG: TV’s reach could go way beyond cervical cancer
-
BG: Genmab on track to become an integrated biopharma company
-
BG: We lift our FV from DKK2,000 to DKK2,150 following the review of our
scenario on TV as well as our updated risk-free rate (0.6% vs 1.6%) and risk premium -
thanks @Stockwatch1
-
The TIL therapy under investigation in this clinical trial (LN-145) is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. After TIL are extracted from the tumor, they are multiplied in a laboratory until billions of TIL are obtained. https://www.iovance.com/clinical/c-145-04-cervical-carcinoma/
-
Yes sounds similar to CAR-T
) that is a difficult treatment though LN 145, isn't it a bit like Car-T?Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind